BNTX vs. GILD, MRNA, BIIB, ARGX, NBIX, QGEN, RGEN, PCVX, RVMD, and EXEL
Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), argenx (ARGX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Exelixis (EXEL). These companies are all part of the "biological products, except diagnostic" industry.
BioNTech (NASDAQ:BNTX) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
BioNTech has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.
Gilead Sciences received 2332 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 42.80% of users gave BioNTech an outperform vote.
In the previous week, Gilead Sciences had 3 more articles in the media than BioNTech. MarketBeat recorded 24 mentions for Gilead Sciences and 21 mentions for BioNTech. BioNTech's average media sentiment score of 0.89 beat Gilead Sciences' score of 0.32 indicating that BioNTech is being referred to more favorably in the media.
BioNTech has a net margin of 4.01% compared to Gilead Sciences' net margin of 1.76%. Gilead Sciences' return on equity of 24.34% beat BioNTech's return on equity.
15.5% of BioNTech shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
BioNTech currently has a consensus price target of $111.70, suggesting a potential upside of 11.03%. Gilead Sciences has a consensus price target of $83.69, suggesting a potential upside of 30.21%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than BioNTech.
Gilead Sciences has higher revenue and earnings than BioNTech. Gilead Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
Summary
Gilead Sciences beats BioNTech on 11 of the 18 factors compared between the two stocks.
Get BioNTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNTech Competitors List
Related Companies and Tools
